Analyst Price Target is $23.75
▲ +148.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Catabasis Pharmaceuticals in the last 3 months. The average price target is $23.75, with a high forecast of $36.00 and a low forecast of $13.00. The average price target represents a 148.69% upside from the last price of $9.55.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Catabasis Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.